Literature DB >> 28185703

BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study.

Umair Khalid1, Lisa Miller Wruck2, Pedro Miguel Quibrera2, Biykem Bozkurt3, Vijay Nambi3, Salim S Virani3, Hani Jneid3, Sunil Agarwal4, Patricia P Chang5, Laura Loehr6, Sukhdeep Singh Basra1, Wayne Rosamond6, Christie M Ballantyne1, Anita Deswal7.   

Abstract

BACKGROUND: Levels of B-type natriuretic peptide (BNP), a prognostic marker in patients with heart failure (HF), are lower among HF patients with obesity or preserved Left Ventricular Ejection Fraction (LVEF). We examined the distribution and prognostic value of BNP across BMI categories in acute decompensated heart failure (ADHF) patients with preserved vs. reduced LVEF.
METHODS: We analyzed data from the Atherosclerosis Risk in Communities (ARIC) HF surveillance study which sampled and adjudicated ADHF hospitalizations in patients aged ≥55years from 4 US communities (2005-2009). We examined 5 BMI categories: underweight (<18.5kg/m2), normal weight (18.5-<25), overweight (25-<30), obese (30-<40) and morbidly obese (≥40) in HF with preserved LVEF (HFpEF) and reduced LVEF (HFrEF). The outcome was 1-year mortality from admission. We used ANCOVA to model log BNP and logistic regression for 1-year mortality, both adjusted for demographics and clinical characteristics.
RESULTS: The cohort included 9820 weighted ADHF hospitalizations (58% HFrEF; 42% HFpEF). BNP levels were lower in HFpEF compared to HFrEF (p<0.001) and decreased as BMI increased within the LVEF groups (p<0.001). After adjustment for covariates, log10 BNP independently predicted 1-year mortality (adjusted OR 1.62 (95% CI 1.17-2.24)) with no significant interaction by BMI or LVEF groups.
CONCLUSIONS: BNP levels correlated inversely with BMI, and were higher in HFrEF compared to HFpEF. Obese patients with HFpEF and ADHF had a significant proportion with BNP levels below clinically accepted thresholds. Nevertheless, BNP was a predictor of mortality in ADHF across groups of BMI in HFpEF and HFrEF. Published by Elsevier B.V.

Entities:  

Keywords:  B-type natriuretic peptide; Body mass index; Heart failure; Obesity

Mesh:

Substances:

Year:  2017        PMID: 28185703      PMCID: PMC5368080          DOI: 10.1016/j.ijcard.2017.01.130

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  29 in total

1.  Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study.

Authors:  Sandeep R Das; Mark H Drazner; Daniel L Dries; Gloria L Vega; Harold G Stanek; Shuaib M Abdullah; Russell M Canham; Anne K Chung; David Leonard; Frank H Wians; James A de Lemos
Journal:  Circulation       Date:  2005-10-04       Impact factor: 29.690

2.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

Authors:  B Levine; J Kalman; L Mayer; H M Fillit; M Packer
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

3.  Wasting as independent risk factor for mortality in chronic heart failure.

Authors:  S D Anker; P Ponikowski; S Varney; T P Chua; A L Clark; K M Webb-Peploe; D Harrington; W J Kox; P A Poole-Wilson; A J Coats
Journal:  Lancet       Date:  1997-04-12       Impact factor: 79.321

4.  Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.

Authors:  Samuel Klein; Lora E Burke; George A Bray; Steven Blair; David B Allison; Xavier Pi-Sunyer; Yuling Hong; Robert H Eckel
Journal:  Circulation       Date:  2004-10-27       Impact factor: 29.690

5.  The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease.

Authors:  Victoria Sheen; Vikas Bhalla; Alisi Tulua-Tata; Meenakshi A Bhalla; Danielle Weiss; Albert Chiu; Omaran Abdeen; Scott Mullaney; Alan Maisel
Journal:  Am Heart J       Date:  2007-02       Impact factor: 4.749

6.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

7.  Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study).

Authors:  Patricia P Chang; Lloyd E Chambless; Eyal Shahar; Alain G Bertoni; Stuart D Russell; Hanyu Ni; Max He; Thomas H Mosley; Lynne E Wagenknecht; Tandaw E Samdarshi; Lisa M Wruck; Wayne D Rosamond
Journal:  Am J Cardiol       Date:  2013-11-09       Impact factor: 2.778

8.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

9.  Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.

Authors:  Kalkidan Bishu; Anita Deswal; Horng H Chen; Martin M LeWinter; Gregory D Lewis; Marc J Semigran; Barry A Borlaug; Steven McNulty; Adrian F Hernandez; Eugene Braunwald; Margaret M Redfield
Journal:  Am Heart J       Date:  2012-10-16       Impact factor: 4.749

10.  No benefit from the obesity paradox for diabetic patients with heart failure.

Authors:  Elisabet Zamora; Josep Lupón; Cristina Enjuanes; Domingo Pascual-Figal; Marta de Antonio; Mar Domingo; Josep Comín-Colet; Joan Vila; Judith Peñafiel; Núria Farré; Núria Alonso; Javier Santesmases; Maribel Troya; Antoni Bayés-Genís
Journal:  Eur J Heart Fail       Date:  2016-06-16       Impact factor: 15.534

View more
  10 in total

1.  Association of B-type natriuretic peptide with coronary plaque subtypes detected by coronary computed tomography angiography in patients with stable chest pain.

Authors:  Yuhai Yang; Caiqin Li; Lei Zhao
Journal:  Int J Cardiovasc Imaging       Date:  2017-04-10       Impact factor: 2.357

Review 2.  Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease.

Authors:  Jessica H Huston; Sanjiv J Shah
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

3.  [Dynamic changes of brain natriuretic peptide concentration and its diagnostic value for heart failure in early phase of acute myocardial infarction].

Authors:  Huidi Li; Dingcheng Xiang; Jinxia Zhang; Tianbing Duan; Feng Long; Aimin Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-01-30

4.  Point-of-care ultrasound modalities in terms of diagnosing acute decompensated heart failure in emergency department; a diagnostic accuracy study.

Authors:  Shervin Farahmand; Ali Abdolhoseini; Ehsan Aliniagerdroudbari; Sepideh Babaniamansour; Alireza Baratloo; Shahram Bagheri-Hariri
Journal:  Intern Emerg Med       Date:  2019-11-30       Impact factor: 3.397

5.  Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial.

Authors:  Vibhu Parcha; Nirav Patel; Rajat Kalra; Sarabjeet S Suri; Garima Arora; Thomas J Wang; Pankaj Arora
Journal:  J Am Heart Assoc       Date:  2021-03-23       Impact factor: 6.106

Review 6.  Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction.

Authors:  Raffaele Altara; Mauro Giordano; Einar S Nordén; Alessandro Cataliotti; Mazen Kurdi; Saeed N Bajestani; George W Booz
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-17       Impact factor: 5.555

7.  Atrial remodelling in heart failure: recent developments and relevance for heart failure with preserved ejection fraction.

Authors:  Felix Hohendanner; Daniel Messroghli; David Bode; Florian Blaschke; Abdul Parwani; Leif-Hendrik Boldt; Frank R Heinzel
Journal:  ESC Heart Fail       Date:  2018-02-19

8.  Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial.

Authors:  Ambarish Pandey; Jarett D Berry; Mark H Drazner; James C Fang; W H Wilson Tang; Justin L Grodin
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

9.  Joint Associations of Obesity and NT-proBNP With the Incidence of Atrial Fibrillation in the ARIC Study.

Authors:  Zakaria Almuwaqqat; Wesley T O'Neal; Faye L Norby; Pamela L Lutsey; Elizabeth Selvin; Elsayed Z Soliman; Lin Y Chen; Alvaro Alonso
Journal:  J Am Heart Assoc       Date:  2019-09-28       Impact factor: 5.501

10.  Highest Obesity Category Associated With Largest Decrease in N-Terminal Pro-B-Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction.

Authors:  Joban Vaishnav; Jessica E Chasler; Yizhen J Lee; Chiadi E Ndumele; Jiun-Ruey Hu; Steven P Schulman; Stuart D Russell; Kavita Sharma
Journal:  J Am Heart Assoc       Date:  2020-07-30       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.